Lactylation-driven TNFR2 expression in regulatory T cells promotes the progression of malignant pleural effusion
And in a 2022 study of people with treatment-resistant bipolar depression, participants depression and functioning improved upon the reversal of insulin resistancea metabolic condition that is more common in people with bipolar disorder (J
At the higher doses, results were very consistent: All participants lost at least 5% of their body weight Around 3 in 4 lost 15% or more With placebo, only around 1 in 4 lost 5% or more Phase 3 update (TRIUMPH-4, 68 weeks, topline results) In December 2025 , Eli Lilly shared early (topline) results from a larger phase 3 study (TRIUMPH-4)
Additionally, ear swelling and weight were significantly suppressed [220]
Additional Financial Assistance for Zepbound Treatment If you are not eligible for the Eli Lilly Zepbound savings program, you still have options: 1